Key facts
- It has raised $130.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($130.0M) in Feb 2021.
- 4 institutional filers report fund marks on Day One Biopharmaceuticals across 21 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Day One Biopharmaceuticals
Create free account
No card required
Funding rounds
1 roundsFeb 2021Early Stage VC (Series B)$130.0M▮
About Day One Biopharmaceuticals
- Industry
- Pharmaceuticals
PA Mark — not yet priced
Day One Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Day One Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Feb 20264 SEC-registered funds reported 21 fair-value marks on Day One Biopharmaceuticals between Apr 2025 and Feb 2026. Filer-level marks and implied $/share are available to Pro members.